Shenzhen KangNing Hospital

Running trials

• Recruiting

  A Study of Brenipatide in Participants With Alcohol Use Disorder

  NCT07219953· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

  NCT07219966· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Not yet recruiting

  Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism

  NCT05947162· Shenzhen Kangning Hospital· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Phase II Study to Evaluate NH102 for Depression

  NCT06842992· Phase 2· Jiangsu Nhwa Pharmaceutical Co., Ltd.· Source

• Completed

  Efficacy, Safety, and Acceptability of Internet-based Cognitive Behavioral Therapy

  NCT05554289· Adai Technology (Beijing) Co., Ltd.· Source

• Completed

  Software-delivered CBT-I for Insomnia Disorder

  NCT05747963· Peking University Sixth Hospital· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source